Literature DB >> 20171895

Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.

Yingjie Zhang1, Jinhong Feng, Chunxi Liu, Lei Zhang, Jie Jiao, Hao Fang, Li Su, Xiaopan Zhang, Jian Zhang, Minyong Li, Binghe Wang, Wenfang Xu.   

Abstract

Histone deacetylases (HDACs) are enzymes involved in tumor genesis and development. Herein, we report a novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as HDACs inhibitors. The preliminary biological screening showed that most of our compounds exhibited potent inhibitory activity against HDACs. Within this series, five compounds, 13a (IC(50)=0.58+/-0.10 microM), 7d (IC(50)=1.00+/-0.16 microM), 8l (IC(50)=1.06+/-0.14 microM), 7i (IC(50)=1.17+/-0.19 microM) and 7a (IC(50)=1.29+/-0.15 microM) possessed better HDACs inhibitory activity than Vorinostat (IC(50)=1.48+/-0.20 microM). So these five compounds could be used as novel lead compounds for further design of HDACs inhibitors. The anti-proliferative activities of a few compounds and the structure-activity relationships are also briefly discussed. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20171895     DOI: 10.1016/j.bmc.2010.01.060

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

1.  Electronically Rich N-Substituted Tetrahydroisoquinoline 3-Carboxylic Acid Esters: Concise Synthesis and Conformational Studies.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Tetrahedron       Date:  2012-01-10       Impact factor: 2.457

2.  Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.

Authors:  Rami A Al-Horani; Akul Y Mehta; Umesh R Desai
Journal:  Eur J Med Chem       Date:  2012-06-23       Impact factor: 6.514

Review 3.  Histone Deacetylase Inhibitors: A Prospect in Drug Discovery.

Authors:  Rakesh Yadav; Pooja Mishra; Divya Yadav
Journal:  Turk J Pharm Sci       Date:  2018-12-31

Review 4.  Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.

Authors:  Berkley E Gryder; Quaovi H Sodji; Adegboyega K Oyelere
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

5.  Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity.

Authors:  Yingjie Zhang; Chunxi Liu; C James Chou; Xuejian Wang; Yuping Jia; Wenfang Xu
Journal:  Chem Biol Drug Des       Date:  2013-07-01       Impact factor: 2.817

6.  Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.

Authors:  Lei Zhang; Yingjie Zhang; C James Chou; Elizabeth S Inks; Xuejian Wang; Xiaoguang Li; Jinning Hou; Wenfang Xu
Journal:  ChemMedChem       Date:  2013-11-12       Impact factor: 3.466

7.  Discovery of a Pair of Diastereomers as Potent HDACs Inhibitors: Determination of Absolute Configuration, Biological Activity Comparison and Computational Study.

Authors:  Yingjie Zhang; Elizabeth S Inks; Mengyuan Zhu; C James Chou; Hao Fang; Minyong Li; Yuemao Shen; Fan Yi; Wenfang Xu
Journal:  RSC Adv       Date:  2013-11-21       Impact factor: 3.361

8.  A Convenient Route to New (Radio)Fluorinated and (Radio)Iodinated Cyclic Tyrosine Analogs.

Authors:  Maria Noelia Chao; Jean-Michel Chezal; Eric Debiton; Damien Canitrot; Tiffany Witkowski; Sophie Levesque; Françoise Degoul; Sébastien Tarrit; Barbara Wenzel; Elisabeth Miot-Noirault; Audrey Serre; Aurélie Maisonial-Besset
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-28

Review 9.  Next-generation of selective histone deacetylase inhibitors.

Authors:  Feifei Yang; Na Zhao; Di Ge; Yihua Chen
Journal:  RSC Adv       Date:  2019-06-24       Impact factor: 4.036

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.